Aman U. Buzdar

53.7k total citations · 15 hit papers
522 papers, 40.0k citations indexed

About

Aman U. Buzdar is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, Aman U. Buzdar has authored 522 papers receiving a total of 40.0k indexed citations (citations by other indexed papers that have themselves been cited), including 354 papers in Oncology, 289 papers in Cancer Research and 152 papers in Genetics. Recurrent topics in Aman U. Buzdar's work include Breast Cancer Treatment Studies (277 papers), Cancer Treatment and Pharmacology (196 papers) and Estrogen and related hormone effects (140 papers). Aman U. Buzdar is often cited by papers focused on Breast Cancer Treatment Studies (277 papers), Cancer Treatment and Pharmacology (196 papers) and Estrogen and related hormone effects (140 papers). Aman U. Buzdar collaborates with scholars based in United States, United Kingdom and Canada. Aman U. Buzdar's co-authors include Gabriel N. Hortobágyi, Vicente Valero, Richard L. Theriault, Terry L. Smith, S. Eva Singletary, Sharon H. Giordano, Kelly K. Hunt, George R. Blumenschein, Henry M. Kuerer and Anthony Howell and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Oncology.

In The Last Decade

Aman U. Buzdar

517 papers receiving 38.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

2010 1.1k citations Jack Cuzick, Ivana Šestak et al. The Lancet Oncology profile →
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy

2007 1.1k citations W. Fraser Symmans, Florentia Peintinger et al. Journal of Clinical Oncology profile →
Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy

1999 1.1k citations Henry M. Kuerer, Kelly K. Hunt et al. Journal of Clinical Oncology profile →
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer

2005 867 citations Aman U. Buzdar, Nuhad K. Ibrahim et al. Journal of Clinical Oncology profile →
Anastrozole Is Superior to Tamoxifen as First-Line Therapy for Advanced Breast Cancer in Postmenopausal Women: Results of a North American Multicenter Randomized Trial

2000 738 citations Aman U. Buzdar et al. Journal of Clinical Oncology profile →
THE IMPACT OF NATIONAL CANCER ACT

1991 712 citations Richard L. Theriault, Aman U. Buzdar et al. profile →
Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer

1999 655 citations Aman U. Buzdar et al. Journal of Clinical Oncology profile →
Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer.

1996 596 citations Gabriel N. Hortobágyi, Aman U. Buzdar et al. Journal of Clinical Oncology profile →
Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen

2009 581 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review

2009 576 citations Shaheenah Dawood, Kristine Broglio et al. Journal of Clinical Oncology profile →
Breast carcinoma in men

2004 554 citations Aman U. Buzdar, Gabriel N. Hortobágyi et al. Cancer profile →
Pharmacogenomic Predictor of Sensitivity to Preoperative Chemotherapy With Paclitaxel and Fluorouracil, Doxorubicin, and Cyclophosphamide in Breast Cancer

2006 553 citations Kenneth R. Hess, W. Fraser Symmans et al. Journal of Clinical Oncology profile →
Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study

2010 546 citations Mitch Dowsett, Jack Cuzick et al. Journal of Clinical Oncology profile →
Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer

2011 540 citations Jack Cuzick, Mitch Dowsett et al. Journal of Clinical Oncology profile →
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype

2017 417 citations W. Fraser Symmans, Kelly K. Hunt et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Aman U. Buzdar

Since Specialization

Citations

This map shows the geographic impact of Aman U. Buzdar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aman U. Buzdar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aman U. Buzdar more than expected).

Fields of papers citing papers by Aman U. Buzdar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aman U. Buzdar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aman U. Buzdar. The network helps show where Aman U. Buzdar may publish in the future.

Co-authorship network of co-authors of Aman U. Buzdar

This figure shows the co-authorship network connecting the top 25 collaborators of Aman U. Buzdar. A scholar is included among the top collaborators of Aman U. Buzdar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aman U. Buzdar. Aman U. Buzdar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action 2020 ·JCI Insight ·Junmei Cairns, James N. Ingle, Tanda M. Dudenkov, Krishna R. Kalari, Erin E. Carlson, Jie Na, Aman U. Buzdar, Mark E. Robson, Matthew J. Ellis, Paul E. Goss, Lois E. Shepherd, (unknown), Matthew P. Goetz, Richard M. Weinshilboum, Hu Li, (unknown), Liewei Wang	22
2	Clinical Trial Characteristics and Barriers to Participant Accrual: The MD Anderson Cancer Center Experience over 30 years, a Historical Foundation for Trial Improvement 2017 ·Clinical Cancer Research ·Chad Tang, Steven I. Sherman, (unknown), Jun Weng, Suzanne E. Davis, David S. Hong, James C. Yao, Aman U. Buzdar, George Wilding, J. Jack Lee	27
3	Genomic characterization of HER2-positive breast cancer and response to neoadjuvant trastuzumab and chemotherapy—results from the ACOSOG Z1041 (Alliance) trial 2017 ·Annals of Oncology ·Robert Lesurf, Obi L. Griffith, Malachi Griffith, Jasreet Hundal, Lee Trani, Mark A. Watson, Rebecca Aft, Matthew J. Ellis, (unknown), Vera J. Suman, Funda Meric‐Bernstam, A. Marilyn Leitch, Judy C. Boughey, Gary Unzeitig, Aman U. Buzdar, Kelly K. Hunt, Elaine R. Mardis	47
4	Modifying the Clinical Research Infrastructure at a Dedicated Clinical Trials Unit: Assessment of Trial Development, Activation, and Participant Accrual 2016 ·Clinical Cancer Research ·Chad Tang, Kenneth R. Hess, (unknown), Suzanne E. Davis, Aman U. Buzdar, Razelle Kurzrock, J. Jack Lee, Funda Meric‐Bernstam, David S. Hong	9
5	Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426) 2016 ·Breast Cancer Research and Treatment ·Erica T. Warner, Karla V. Ballman, Carrie Strand, Judy C. Boughey, Aman U. Buzdar, Lisa A. Carey, William M. Sikov, Ann H. Partridge	43
6	Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial 2013 ·The Lancet Oncology ·Aman U. Buzdar, Vera J. Suman, Funda Meric‐Bernstam, A. Marilyn Leitch, Matthew J. Ellis, Judy C. Boughey, Gary Unzeitig, Melanie Royce, Linda McCall, Michael S. Ewer, Kelly K. Hunt	120
7	Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial 2012 ·The Lancet Oncology ·Paul E. Goss, Ian E. Smith, Joyce O’Shaughnessy, Bent Ejlertsen, Manfred Kaufmann, Frances Boyle, Aman U. Buzdar, P. Fumoleau, William J. Gradishar, Miguel Martín, Beverly Moy, Martine Piccart, Kathleen I. Pritchard, Deborah Lindquist, Yanin Chávarri-Guerra, Gursel Aktan, Erica Rappold, Lisa S. Williams, Dianne M. Finkelstein	100
8	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial 2011 ·Journal of Clinical Oncology ·Alistair Ring, Ivana Šestak, Michael Baum, Anthony Howell, Aman U. Buzdar, Mitch Dowsett, John Forbes, Jack Cuzick	50
9	Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline‐ and nonanthracycline‐based regimens for HER2‐positive breast cancer 2011 ·Cancer ·Soley Bayraktar, Ana M. Gonzalez‐Angulo, Xiudong Lei, Aman U. Buzdar, Vicente Valero, Amal Melhem‐Bertrandt, Henry M. Kuerer, Gabriel N. Hortobágyi, Ayşegül A. Şahin, Funda Meric‐Bernstam	52
10	Functional Genetic Polymorphisms in the Aromatase Gene CYP19 Vary the Response of Breast Cancer Patients to Neoadjuvant Therapy with Aromatase Inhibitors 2010 ·Cancer Research ·Liewei Wang, Katarzyna A. Ellsworth, Irene Moon, Linda L. Pelleymounter, Bruce W. Eckloff, Yvette N. Martin, Brooke L. Fridley, Gregory D. Jenkins, Anthony Batzler, Vera J. Suman, Saranya Ravi, J. Michael Dixon, William R. Miller, Eric D. Wieben, Aman U. Buzdar, Richard M. Weinshilboum, James N. Ingle	92
11	Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen breakdown → 2009 ·Journal of Clinical Oncology ·Mitch Dowsett, Jack Cuzick, J. N. Ingle, Alan S. Coates, John Forbes, Judith M. Bliss, Marc Buyse, Michael Baum, Aman U. Buzdar, Marco Colleoni, R. Charles Coombes, Claire Snowdon, Michael Gnant, R. Jakesz, Manfred Kaufmann, Francesco Boccardo, Jon Godwin, Christina Davies, Richárd Pető	581
12	Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer 2009 ·Annals of Oncology ·Aman U. Buzdar	66
13	Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival Outcomes 2009 ·Clinical Cancer Research ·Elizabeth A. Mittendorf, Yun Wu, Maurizio Scaltriti, Funda Meric‐Bernstam, Kelly K. Hunt, Shaheenah Dawood, Francisco J. Esteva, Aman U. Buzdar, Huiqin Chen, (unknown), Gabriel N. Hortobágyi, José Baselga, Ana M. González-Angulo	263
14	Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab 2008 ·Annals of Oncology ·Florentia Peintinger, Aman U. Buzdar, Henry M. Kuerer, Jaime Mejia, Christos Hatzis, Ana M. González-Angulo, Lajos Pusztai, Francisco J. Esteva, Shaheenah Dawood, (unknown), Gabriel N. Hortobágyi, W. Fraser Symmans	34
15	Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin 2007 ·Cancer ·Shaheenah Dawood, Ana M. Gonzalez‐Angulo, Florentia Peintinger, Kristine Broglio, W. Fraser Symmans, Shu‐Wan Kau, Rabiul Islam, Gabriel N. Hortobágyi, Aman U. Buzdar	46
16	Novel Clinical Trial Designs for Treatment of Ductal Carcinoma In Situ of the Breast with Trastuzumab (Herceptin) 2007 ·The Breast Journal ·Ricardo J. Gonzalez, Aman U. Buzdar, W. Fraser Symmans, Tina Yen, Kristine Broglio, Anthony Lucci, Francisco J. Esteva, Guosheng Yin, Henry M. Kuerer	17
17	TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. 2005 ·PubMed ·Yasuji Yamamoto, Jiro Shibata, Kazuhiko Yonekura, (unknown), Akihiro Hashimoto, Yoshimi Aoyagi, Konstanty Wierzba, Shingo Yano, Tetsuji Asao, Aman U. Buzdar, (unknown)	29
18	Total RNA yield and microarray gene expression profiles from fine‐needle aspiration biopsy and core‐needle biopsy samples of breast carcinoma 2003 ·Cancer ·W. Fraser Symmans, Mark Ayers, Edwin Clark, James Stec, Kenneth R. Hess, Nour Sneige, Thomas A. Buchholz, Savitri Krishnamurthy, Nuhad K. Ibrahim, Aman U. Buzdar, Richard L. Theriault, (unknown), Eva Thomas, Karin Gwyn, Marjorie C. Green, (unknown), Gabriel N. Hortobágyi, Lajos Pusztai	140
19	M.D.Anderson cancer care series 2001 ·Springer eBooks ·Aman U. Buzdar, (unknown)	3
20	Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Guérin. 1978 ·PubMed ·G. N. Hortobagyi, H. Y. Yap, George R. Blumenschein, J. U. Gutterman, Aman U. Buzdar, Charles K. Tashima, E. M. Hersh	9

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact